Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004001 · ClinicalTrials.gov registry record · Phase 3
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 3 study of Prostate Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
- 16
- Study locations
NCT00004001 is a Phase 3 study of Prostate Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 770 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (27% higher). The trial reports 16 study locations across 9 states.
The verdict
NCT00004001, a Phase 3 study of Prostate Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
- 16
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known whether estramustine plus docetaxel is more effective than mitoxantrone plus prednisone for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of estramustine plus docetaxel with that of mitoxantrone plus prednisone in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG mitoxantrone
- DRUG estramustine
Study Locations (16)
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
- CCOP - Iowa Oncology Research Association - Des Moines
- Siouxland Hematology-Oncology - Sioux City
North Dakota
- Medcenter One Health System - Bismarck
- CCOP - Merit Care Hospital - Fargo
- Altru Health System - Grand Forks
Illinois
- CCOP - Illinois Oncology Research Association - Peoria
- CCOP - Carle Cancer Center - Urbana
Minnesota
- Mayo Clinic Cancer Center - Rochester
- CentraCare Health Plaza - Saint Cloud
South Dakota
- Rapid City Regional Hospital - Rapid City
- CCOP - Sioux Community Cancer Consortium - Sioux Falls
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
Florida
- Mayo Clinic - Jacksonville
Nebraska
- CCOP - Missouri Valley Cancer Consortium - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 1999-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004001
The ClinicalTrials.gov registry entry for NCT00004001 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 770 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (27% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which prednisone is the first listed.
NCT00004001 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Iowa, North Dakota, Illinois.
Frequently Asked Questions
What is clinical trial NCT00004001 about?
NCT00004001 is a clinical study titled "S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known whether estramustine plus docetaxel is more effec...
What is the current status of trial NCT00004001?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 1999-10. Estimated completion is 2007-01.
What conditions does trial NCT00004001 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00004001?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), mitoxantrone (DRUG), estramustine (DRUG).
Who is sponsoring clinical trial NCT00004001?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004001 being conducted?
This trial has 16 study locations across Arizona, Florida, Illinois, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.